Pathogenic bacterium in the gut

"Pathogenic bacterium in the gut" is not a single molecular target but rather refers collectively to various bacterial species within the intestinal tract that have been associated with human disease. These organisms can cause infection directly through colonization and toxin production (Klebsiella pneumoniae, Bacteroides fragilis, certain strains of Escherichia coli), contribute to inflammation, disrupt normal microbial balance ("dysbiosis"), and play roles in conditions ranging from acute gastroenteritis to chronic inflammatory diseases. The term encompasses many different taxa across several phyla—most notably Proteobacteria (E. coli, Klebsiella), Bacteroidetes (Bacteroides fragilis), Firmicutes (Clostridium difficile)—and does not refer to a unique protein/receptor/enzyme suitable as a classic drug target.[1][3][4] Instead, therapeutic strategies often aim at reducing their abundance using antibiotics or modulating overall community structure via probiotics/prebiotics. Note: This entry is considered incorrect as a canonical drug target because it describes an entire group/class rather than an individual molecular entity such as a receptor or enzyme.[1][3]

Other names

Gut pathogenic bacteriaIntestinal pathogenic bacteriaEnteric pathogensHarmful gut bacteria

Drugs targeting pathogenic gut bacteria typically act by one or more mechanisms such as: - Inhibition of bacterial cell wall synthesis (e.g., beta-lactams like amoxicillin) - Inhibition of DNA replication/transcription/translation (e.g., fluoroquinolones like ciprofloxacin; metronidazole for anaerobes) - Disruption of bacterial metabolic pathways